Laparoscopic Versus Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Update from the Class-01 Randomized Controlled Trial

2020 ◽  
Author(s):  
Chang-Ming Huang ◽  
Hao Liu ◽  
Yanfeng Hu ◽  
Yihong Sun ◽  
Xiangqian Su ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Randomized Controlled Trial ◽  
Advanced Gastric Cancer ◽  
Distal Gastrectomy ◽  
Controlled Trial ◽  
Locally Advanced ◽  
Open Distal Gastrectomy ◽  
Randomized Controlled ◽  
Locally Advanced Gastric Cancer

Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer: a case–control study

2011 ◽  
Vol 63 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Marco Scatizzi ◽  
Katrin C. Kröning ◽  
Elisa Lenzi ◽  
Luca Moraldi ◽  
Stefano Cantafio ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Case Control Study ◽  
Distal Gastrectomy ◽  
Locally Advanced ◽  
Case Control ◽  
Open Distal Gastrectomy ◽  
Locally Advanced Gastric Cancer ◽  
Control Study

Morbidity and mortality after laparoscopy-assisted and open distal gastrectomy for stage I gastric cancer: Results from a multicenter randomized controlled trial (KLASS-01).

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 4-4 ◽  
Author(s):  
Hyuk-Joon Lee ◽  
Hyung-Ho Kim ◽  
Sang Uk Han ◽  
Min-Chan Kim ◽  
Woo Jin Hyung ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Randomized Controlled Trial ◽  
Distal Gastrectomy ◽  
Controlled Trial ◽  
Clinical Stage ◽  
Wound Complication ◽  
Stage I ◽  
Open Distal Gastrectomy ◽  
Randomized Controlled ◽  
Multicenter Randomized Controlled Trial

4 Background: Laparoscopy assisted distal gastrectomy (LADG) is widely performed for gastric cancer in Eastern countries, although large scale prospective data are still lacking. We conducted a phase III, multicenter randomized controlled trial (KLASS-01) to compare the short and long term outcomes of LADG versus open distal gastrectomy (ODG) in patients with clinical stage I gastric cancer in Korea. Methods: The primary end point was 5-year overall survival. The morbidity within 30 postoperative days and the surgical mortality were compared to evaluate the safety of LADG as a secondary end point. A total of 1,416 patients were randomly assigned to the LADG group (n = 705) or the ODG group (n = 711) between Feb 1, 2006 and Aug 31, 2010. Results: 1,256 were eligible for per protocol (PP) analysis (644 and 612, respectively). The overall complication rate was significantly lower in the LADG group (LADG vs. ODG; 13.0% vs. 19.9%, P =.001). In detail, the wound complication rate of the LADG group was significantly lower than that of the ODG group (3.1% vs. 7.7%, P <.001). The major intra-abdominal complication (7.6% vs. 10.3%, P =.095) and mortality rates (0.6% vs. 0.3%, P =.450) were similar between groups. Modified intention-to-treat analysis showed similar results with PP analysis. Conclusions: LADG for patients with clinical stage I gastric cancer is safe and has a benefit of lower occurrence of wound complication compared with conventional ODG. Clinical trial information: NCT00452751.

Sign in / Sign up

Export Citation Format

Share Document